FRLN - Freeline gains on non-binding buyout offer from Syncona
2023-10-18 12:10:20 ET
More on Freeline Therapeutics
- Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript
- Freeline posts early data for gene therapy in Gaucher disease
- Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M
- Seeking Alpha’s Quant Rating on Freeline Therapeutics
- Historical earnings data for Freeline Therapeutics
For further details see:
Freeline gains on non-binding buyout offer from Syncona